Poussot Rodolphe Jean 4

What Happened

• Rodolphe Poussot, SVP of Strategy & Corporate Development at West Pharmaceutical (WST), had 82.299 restricted stock units convert into common shares on Feb 18, 2026.
• To cover tax withholding, 27.809 of those shares were surrendered at $248.26 per share (total withheld ≈ $6,904), leaving a net delivery of about 54.49 shares.
• This was a vesting/conversion of RSUs (not an open-market sale or purchase) — a routine compensation event rather than a directional trade.

Key Details

• Transaction date: 2026-02-18; tax withholding price: $248.26/share; tax withheld value: $6,904.
• Shares converted/vested: 82.299 RSUs → 82.299 common shares.
• Shares withheld for taxes: 27.809 (disposed) → net shares delivered ≈ 54.49.
• Shares owned after transaction: not specified in the provided filing.
• Footnotes: F1 — RSUs convert one-for-one into common stock; F2 — original grant was 329 RSUs on Feb 18, 2025, vesting in four equal annual installments (plus dividend equivalents).
• Transaction codes: M = exercise/conversion of derivative (RSU conversion), F = shares (or cash) transferred to cover tax withholding.
• Filing timeliness: report filed 2026-02-19 for a 2026-02-18 transaction (appears timely).

Context

• This was effectively a cashless/withholding settlement of vested RSUs (shares withheld to cover tax obligations), not a sale into the market — common for equity compensation.
• Such vesting events are routine compensation and do not by themselves indicate insider buying or selling sentiment.